adalimumab vs SOR102

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Ulcerative Colitis

Shared mechanism: TNF-alpha · full Ulcerative Colitis pipeline

adalimumab · Humira

Marketed by AbbVie and partners

Approved in Ulcerative Colitismonoclonal antibody (fully human IgG1)
Partial signal

NCT00385736 · Phase 3 · completed

Design is strong (randomized, quadruple-blind, placebo-controlled, n=576, hard endoscopic/clinical Mayo remission endpoint), but the primary endpoint result was discordant across the two pre-specified dose-vs-placebo comparisons: one significant, one not. A well-designed trial with a mixed result is capped at moderate rather than strong.

Next expected readout: September 2027 · NCT06257875 (registry estimate)

Reported efficacy

Proportion of Participants Who Achieved Clinical Remission Per Mayo Score at Week 8; Proportion of Participants Who Achieved Clinical Remission Per Mayo Score at Week 52: Proportion of Participants Who Achieved Clinical Remission Per Mayo Score at Week 8 (Week 8): Adalimumab 160/80/40 16.5% vs Placebo 9.3%; p=0.019 (Adalimumab 160/80/40 vs Placebo) (met)

Result source: NCT00408629

SOR102

Developed by Sorriso Pharmaceuticals

Phase 1 in Ulcerative ColitisBiologic (oral dual TNFα/IL-23(p19) inhibitor)
Weak signal

NCT06080048 · Phase 1 · completed

Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source. Its registered primary outcome on ClinicalTrials.gov is "Treatment Emergent Adverse Events following oral dosing". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.

Reported efficacy

Treatment Emergent Adverse Events following oral dosing (Up to 6 weeks in Part 3 or at the time of study discontinuation): First-in-human phase 1. Part 1 (healthy participants): treatment-emergent adverse events in 3/24 (13%) receiving SOR102 versus 2/8 (25%) receiving placebo. Part 2: no treatment-emergent adverse events in the 10 participants receiving twice-daily SOR102. Part 3 (ulcerative colitis patients): at least one adverse event in 7/16 (44%) treated with SOR102 and 3/6 (50%) receiving placebo. Rates of clinical response ranged from 29% to 67%, depending on the definition applied.

Result source: NCT06080048

Results for Ulcerative Colitis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointadalimumabSOR102
Clinical remission (induction)10% vs 11.5%−1.5 vs placebo160 mg/80 mg · wk 8 · n 90NCT00853099
6 other results
  • 13.8% vs 11.5% 80 mg/40 mg · wk 8 · n 87 · Phase 3 · primary NCT00853099
  • 10% vs 9.2% 80/40 · wk 8 · n 130 · Phase 3 · primary NCT00385736
  • 18.5% vs 9.2% 160/80/40 · wk 8 · n 130 · Phase 3 · primary NCT00385736
  • 16.5% vs 9.3% 160/80/40 · wk 8 · n 248 · Phase 3 · primary NCT00408629
  • 10% vs 11.5% 160 mg/80 mg · wk 8 · n 90 · Phase 3 · secondary NCT00853099
  • 13.8% vs 11.5% 80 mg/40 mg · wk 8 · n 87 · Phase 3 · secondary NCT00853099
—Not reported
Clinical remission (maintenance)20% vs 7.3%+12.7 vs placebo160 mg/80 mg · wk 52 · n 90NCT00853099
14 other results
  • 26.4% vs 7.3% 80 mg/40 mg · wk 52 · n 87 · Phase 3 · primary NCT00853099
  • 17.3% vs 8.5% 160/80/40 · wk 52 · n 248 · Phase 3 · primary NCT00408629
  • 29% vs 33.3% standard dose · wk 52 · n 31 · Phase 3 · primary NCT02065557
  • 45.2% vs 33.3% high dose · wk 52 · n 31 · Phase 3 · primary NCT02065557
  • 27.3% vs 33.3% standard dose · wk 52 · n 33 · Phase 3 · primary NCT02065557
  • 42.9% vs 33.3% high dose · wk 52 · n 35 · Phase 3 · primary NCT02065557
  • 20% vs 7.3% 160 mg/80 mg · wk 52 · n 90 · Phase 3 · secondary NCT00853099
  • 17.8% vs 8.3% 160 mg/80 mg · wk 32 · n 90 · Phase 3 · secondary NCT00853099
  • 26.4% vs 7.3% 80 mg/40 mg · wk 52 · n 87 · Phase 3 · secondary NCT00853099
  • 17.2% vs 8.3% 80 mg/40 mg · wk 32 · n 87 · Phase 3 · secondary NCT00853099
  • 42.9% vs 37.5% standard dose · wk 52 · n 21 · Phase 3 · secondary NCT02065557
  • 45.5% vs 37.5% high dose · wk 52 · n 22 · Phase 3 · secondary NCT02065557
  • 42.9% vs 37.5% standard dose · wk 52 · n 21 · Phase 3 · secondary NCT02065557
  • 44% vs 37.5% high dose · wk 52 · n 25 · Phase 3 · secondary NCT02065557
—Not reported
Clinical response (induction)50% vs 35.4%+14.6 vs placebo160 mg/80 mg · wk 8 · n 90NCT00853099
4 other results
  • 42.5% vs 35.4% 80 mg/40 mg · wk 8 · n 87 · Phase 3 · secondary NCT00853099
  • 54.6% vs 44.6% 160/80/40 · wk 8 · n 130 · Phase 3 · secondary NCT00385736
  • 51.5% vs 44.6% 80/40 · wk 8 · n 130 · Phase 3 · secondary NCT00385736
  • 50.4% vs 34.6% 160/80/40 · wk 8 · n 248 · Phase 3 · secondary NCT00408629
—Not reported
Endoscopic improvement (induction)44.4% vs 30.2%+14.2 vs placebo160 mg/80 mg · wk 8 · n 90NCT00853099
2 other results
  • 39.1% vs 30.2% 80 mg/40 mg · wk 8 · n 87 · Phase 3 · secondary NCT00853099
  • 41.1% vs 31.7% 160/80/40 · wk 8 · n 248 · Phase 3 · secondary NCT00408629
—Not reported
Corticosteroid-free remission (maintenance)13.3% vs 5.7%+7.6 vs placebo160/80/40 · wk 52 · n 150NCT00408629
5 other results
  • 13.3% vs 5.7% 160/80/40 · wk 52 · n 150 · Phase 3 · secondary NCT00408629
  • 30.8% vs 40% standard dose · wk 52 · n 13 · Phase 3 · secondary NCT02065557
  • 31.3% vs 40% high dose · wk 52 · n 16 · Phase 3 · secondary NCT02065557
  • 26.7% vs 40% standard dose · wk 52 · n 15 · Phase 3 · secondary NCT02065557
  • 35.3% vs 40% high dose · wk 52 · n 17 · Phase 3 · secondary NCT02065557
—Not reported

Clinical remission (induction)

adalimumab
10% vs 11.5%−1.5 vs placebo160 mg/80 mg · wk 8 · n 90NCT00853099
6 other results
  • 13.8% vs 11.5% 80 mg/40 mg · wk 8 · n 87 · Phase 3 · primary NCT00853099
  • 10% vs 9.2% 80/40 · wk 8 · n 130 · Phase 3 · primary NCT00385736
  • 18.5% vs 9.2% 160/80/40 · wk 8 · n 130 · Phase 3 · primary NCT00385736
  • 16.5% vs 9.3% 160/80/40 · wk 8 · n 248 · Phase 3 · primary NCT00408629
  • 10% vs 11.5% 160 mg/80 mg · wk 8 · n 90 · Phase 3 · secondary NCT00853099
  • 13.8% vs 11.5% 80 mg/40 mg · wk 8 · n 87 · Phase 3 · secondary NCT00853099
SOR102
—Not reported

Clinical remission (maintenance)

adalimumab
20% vs 7.3%+12.7 vs placebo160 mg/80 mg · wk 52 · n 90NCT00853099
14 other results
  • 26.4% vs 7.3% 80 mg/40 mg · wk 52 · n 87 · Phase 3 · primary NCT00853099
  • 17.3% vs 8.5% 160/80/40 · wk 52 · n 248 · Phase 3 · primary NCT00408629
  • 29% vs 33.3% standard dose · wk 52 · n 31 · Phase 3 · primary NCT02065557
  • 45.2% vs 33.3% high dose · wk 52 · n 31 · Phase 3 · primary NCT02065557
  • 27.3% vs 33.3% standard dose · wk 52 · n 33 · Phase 3 · primary NCT02065557
  • 42.9% vs 33.3% high dose · wk 52 · n 35 · Phase 3 · primary NCT02065557
  • 20% vs 7.3% 160 mg/80 mg · wk 52 · n 90 · Phase 3 · secondary NCT00853099
  • 17.8% vs 8.3% 160 mg/80 mg · wk 32 · n 90 · Phase 3 · secondary NCT00853099
  • 26.4% vs 7.3% 80 mg/40 mg · wk 52 · n 87 · Phase 3 · secondary NCT00853099
  • 17.2% vs 8.3% 80 mg/40 mg · wk 32 · n 87 · Phase 3 · secondary NCT00853099
  • 42.9% vs 37.5% standard dose · wk 52 · n 21 · Phase 3 · secondary NCT02065557
  • 45.5% vs 37.5% high dose · wk 52 · n 22 · Phase 3 · secondary NCT02065557
  • 42.9% vs 37.5% standard dose · wk 52 · n 21 · Phase 3 · secondary NCT02065557
  • 44% vs 37.5% high dose · wk 52 · n 25 · Phase 3 · secondary NCT02065557
SOR102
—Not reported

Clinical response (induction)

adalimumab
50% vs 35.4%+14.6 vs placebo160 mg/80 mg · wk 8 · n 90NCT00853099
4 other results
  • 42.5% vs 35.4% 80 mg/40 mg · wk 8 · n 87 · Phase 3 · secondary NCT00853099
  • 54.6% vs 44.6% 160/80/40 · wk 8 · n 130 · Phase 3 · secondary NCT00385736
  • 51.5% vs 44.6% 80/40 · wk 8 · n 130 · Phase 3 · secondary NCT00385736
  • 50.4% vs 34.6% 160/80/40 · wk 8 · n 248 · Phase 3 · secondary NCT00408629
SOR102
—Not reported

Endoscopic improvement (induction)

adalimumab
44.4% vs 30.2%+14.2 vs placebo160 mg/80 mg · wk 8 · n 90NCT00853099
2 other results
  • 39.1% vs 30.2% 80 mg/40 mg · wk 8 · n 87 · Phase 3 · secondary NCT00853099
  • 41.1% vs 31.7% 160/80/40 · wk 8 · n 248 · Phase 3 · secondary NCT00408629
SOR102
—Not reported

Corticosteroid-free remission (maintenance)

adalimumab
13.3% vs 5.7%+7.6 vs placebo160/80/40 · wk 52 · n 150NCT00408629
5 other results
  • 13.3% vs 5.7% 160/80/40 · wk 52 · n 150 · Phase 3 · secondary NCT00408629
  • 30.8% vs 40% standard dose · wk 52 · n 13 · Phase 3 · secondary NCT02065557
  • 31.3% vs 40% high dose · wk 52 · n 16 · Phase 3 · secondary NCT02065557
  • 26.7% vs 40% standard dose · wk 52 · n 15 · Phase 3 · secondary NCT02065557
  • 35.3% vs 40% high dose · wk 52 · n 17 · Phase 3 · secondary NCT02065557
SOR102
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

SOR102: no structured comparison results are available for Ulcerative Colitis.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. adalimumab: 4 of 4 rows · SOR102: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricadalimumab
Dropout rate
6.9%160/80/40a
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 18 more results
9.2%80/40
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
37.6%160/80/40
NCT00408629 · Phase 3 · Ulcerative Colitis · phase 3
—Adalimumab Group - Double-Blind Pe
NCT00408629 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
52.5%
NCT02632175 · Phase 3 · monotherapy
—high dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
—open-label high dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
—standard dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
—high dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
—standard dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
10.3%Induction (Main Study + Japan Sub-
NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3
12.4%Induction (Main Study + Japan Sub-
NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3
—Maintenance (Main Study + Japan Su
NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3
—Maintenance (Main Study + Japan Su
NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3
—Maintenance (Main Study): TDM Regi
NCT02065622 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
56.4%40 mg EOW/EW
NCT00573794 · Phase 3 · monotherapy
34.1%160 mg/80 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
33.3%80 mg/40 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
23.8%
NCT01550965 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
Discontinued due to AEs
3.1%160/80/40a
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 18 more results
4.6%80/40
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
5%160/80/40
NCT00408629 · Phase 3 · Ulcerative Colitis · phase 3
—Adalimumab Group - Double-Blind Pe
NCT00408629 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
—
NCT02632175 · Phase 3 · monotherapy
—high dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
—open-label high dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
—standard dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
—high dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
—standard dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
3.3%Induction (Main Study + Japan Sub-
NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3
3.4%Induction (Main Study + Japan Sub-
NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3
—Maintenance (Main Study + Japan Su
NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3
—Maintenance (Main Study + Japan Su
NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3
—Maintenance (Main Study): TDM Regi
NCT02065622 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
13.8%40 mg EOW/EW
NCT00573794 · Phase 3 · monotherapy
14.3%160 mg/80 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
10.3%80 mg/40 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
5.6%
NCT01550965 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
Serious AEs
4%160/80/40a
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 18 more results
3.8%80/40
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
—160/80/40
NCT00408629 · Phase 3 · Ulcerative Colitis · phase 3
12.1%Adalimumab Group - Double-Blind Pe
NCT00408629 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
27.1%
NCT02632175 · Phase 3 · monotherapy
7.8%high dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
5.6%open-label high dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
15.6%standard dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
13.9%high dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
15.2%standard dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
3.8%Induction (Main Study + Japan Sub-
NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3
5%Induction (Main Study + Japan Sub-
NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3
12.6%Maintenance (Main Study + Japan Su
NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3
12.8%Maintenance (Main Study + Japan Su
NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3
9.9%Maintenance (Main Study): TDM Regi
NCT02065622 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
26.7%40 mg EOW/EW
NCT00573794 · Phase 3 · monotherapy
11.1%160 mg/80 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
16.1%80 mg/40 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
14.5%
NCT01550965 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
Most frequent reported AEs
160/80/40a
colitis ulcerative 4% (placebo 3.6%)
fatigue 4% (placebo 2.2%)
headache 3.1% (placebo 7.2%)
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 17 more results
80/40
headache 6.9% (placebo 7.2%)
colitis ulcerative 5.4% (placebo 3.6%)
nasopharyngitis 4.6% (placebo 1.8%)
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
nasopharyngitis 17.5% (placebo 10.4%)
colitis ulcerative 16.3% (placebo 22.3%)
headache 8.6% (placebo 14.2%)
NCT00408629 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
colitis ulcerative 33.9%
upper respiratory tract infection 27.1%
nasopharyngitis 22%
NCT02632175 · Phase 3 · monotherapy
high dose
headache 9.8% (placebo 16.7%)
anaemia 5.9% (placebo 8.3%)
nausea 5.9% (placebo 0%)
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
open-label high dose
headache 22.2% (placebo 16.7%)
abdominal pain 11.1% (placebo 8.3%)
oropharyngeal pain 11.1% (placebo 0%)
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
standard dose
headache 12.5% (placebo 16.7%)
colitis ulcerative 6.3% (placebo 16.7%)
nasopharyngitis 6.3% (placebo 8.3%)
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
high dose
colitis ulcerative 11.1% (placebo 16.7%)
nasopharyngitis 11.1% (placebo 8.3%)
upper respiratory tract infection 11.1% (placebo 16.7%)
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
standard dose
headache 18.2% (placebo 16.7%)
c-reactive protein increased 9.1% (placebo 0%)
colitis ulcerative 9.1% (placebo 16.7%)
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
headache 8.4%
nasopharyngitis 5.1%
arthralgia 3.1%
NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3
headache 6.1%
colitis ulcerative 5.3%
nasopharyngitis 4.2%
NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3
colitis ulcerative 13.4%
nasopharyngitis 13.1%
arthralgia 6.6%
NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3
colitis ulcerative 17.4%
nasopharyngitis 13.6%
arthralgia 6.7%
NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3
colitis ulcerative 15.2%
nasopharyngitis 7.3%
upper respiratory tract infection 6%
NCT02065622 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
40 mg EOW/EW
colitis ulcerative 30.4%
viral upper respiratory tract infection 19.4%
arthralgia 10.5%
NCT00573794 · Phase 3 · monotherapy
160 mg/80 mg
nasopharyngitis 33.3% (placebo 21.9%)
iron deficiency anaemia 8.9% (placebo 7.3%)
headache 7.8% (placebo 6.3%)
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
80 mg/40 mg
nasopharyngitis 21.8% (placebo 21.9%)
injection site reaction 8% (placebo 2.1%)
dental caries 6.9% (placebo 5.2%)
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
colitis ulcerative 13.2%
headache 13%
nasopharyngitis 8%
NCT01550965 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3

Notes

  1. aPopulation comparability has not been reviewed for 2 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

adalimumab

Clinical Remission 10% (n=90) vs 11.5% (n=96) placebo @ 8wk160 mg/80 mg
responder rate · % of participants
Induction
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 6 more results
10% (n=90) vs 11.5% (n=96) placebo @ 8wk160 mg/80 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
13.8% (n=87) vs 11.5% (n=96) placebo @ 8wk80 mg/40 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
13.8% (n=87) vs 11.5% (n=96) placebo @ 8wk80 mg/40 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
10% (n=130) vs 9.2% (n=130) placebo @ 8wk80/40
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
18.5% (n=130) vs 9.2% (n=130) placebo @ 8wk160/80/40
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
16.5% (n=248) vs 9.3% (n=246) placebo @ 8wk160/80/40
NCT00408629 · Phase 3 · Ulcerative Colitis · phase 3
Clinical Response 50% (n=90) vs 35.4% (n=96) placebo @ 8wk160 mg/80 mg
responder rate · % of participants
Induction
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 4 more results
42.5% (n=87) vs 35.4% (n=96) placebo @ 8wk80 mg/40 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
54.6% (n=130) vs 44.6% (n=130) placebo @ 8wk160/80/40
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
51.5% (n=130) vs 44.6% (n=130) placebo @ 8wk80/40
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
50.4% (n=248) vs 34.6% (n=246) placebo @ 8wk160/80/40
NCT00408629 · Phase 3 · Ulcerative Colitis · phase 3
Endoscopic Improvement 46.9% (n=130) vs 41.5% (n=130) placebo @ 8wk160/80/40
event count · % of participants
Induction
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 1 more result
37.7% (n=130) vs 41.5% (n=130) placebo @ 8wk80/40
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
Rectal Bleeding Subscore 0 1 77.7% (n=130) vs 66.2% (n=130) placebo @ 8wk160/80/40
event count · % of participants
Induction
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 1 more result
70% (n=130) vs 66.2% (n=130) placebo @ 8wk80/40
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
Physician Global Assessment Subscore 0 1 60% (n=130) vs 46.9% (n=130) placebo @ 8wk160/80/40
event count · % of participants
Induction
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 1 more result
53.8% (n=130) vs 46.9% (n=130) placebo @ 8wk80/40
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
Stool Frequency Subscore 0 1 48.5% (n=130) vs 37.7% (n=130) placebo @ 8wk160/80/40
event count · % of participants
Induction
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 1 more result
36.2% (n=130) vs 37.7% (n=130) placebo @ 8wk80/40
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
IBDQ 42.2% (n=90) vs 39.6% (n=96) placebo @ 8wk160 mg/80 mg
responder rate · % of participants
Induction
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 4 more results
48.3% (n=87) vs 39.6% (n=96) placebo @ 8wk80 mg/40 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
60.8% (n=130) vs 57.7% (n=130) placebo @ 8wk160/80/40
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
53.8% (n=130) vs 57.7% (n=130) placebo @ 8wk80/40
NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
58.1% (n=248) vs 45.5% (n=246) placebo @ 8wk160/80/40
NCT00408629 · Phase 3 · Ulcerative Colitis · phase 3
Clinical Remission 20% (n=90) vs 7.3% (n=96) placebo @ 52wk160 mg/80 mg
responder rate · % of participants
Maintenance
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 14 more results
17.8% (n=90) vs 8.3% (n=96) placebo @ 32wk160 mg/80 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
20% (n=90) vs 7.3% (n=96) placebo @ 52wk160 mg/80 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
26.4% (n=87) vs 7.3% (n=96) placebo @ 52wk80 mg/40 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
17.2% (n=87) vs 8.3% (n=96) placebo @ 32wk80 mg/40 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
26.4% (n=87) vs 7.3% (n=96) placebo @ 52wk80 mg/40 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
17.3% (n=248) vs 8.5% (n=246) placebo @ 52wk160/80/40
NCT00408629 · Phase 3 · Ulcerative Colitis · phase 3
29% (n=31) vs 33.3% (n=12) placebo @ 52wkstandard dose
NCT02065557 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
45.2% (n=31) vs 33.3% (n=12) placebo @ 52wkhigh dose
NCT02065557 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
27.3% (n=33) vs 33.3% (n=12) placebo @ 52wkstandard dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
42.9% (n=35) vs 33.3% (n=12) placebo @ 52wkhigh dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
42.9% (n=21) vs 37.5% (n=8) placebo @ 52wkstandard dose
NCT02065557 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
45.5% (n=22) vs 37.5% (n=8) placebo @ 52wkhigh dose
NCT02065557 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
42.9% (n=21) vs 37.5% (n=8) placebo @ 52wkstandard dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
44% (n=25) vs 37.5% (n=8) placebo @ 52wkhigh dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
Sustained Clinical Remission 8.5% (n=248) vs 4.1% (n=246) placebo160/80/40
responder rate · % of participants
NCT00408629 · Phase 3 · Ulcerative Colitis · phase 3
Clinical Response 37.8% (n=90) vs 20.8% (n=96) placebo @ 32wk160 mg/80 mg
responder rate · % of participants
Maintenance
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 8 more results
31.1% (n=90) vs 17.7% (n=96) placebo @ 52wk160 mg/80 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
33.3% (n=87) vs 20.8% (n=96) placebo @ 32wk80 mg/40 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
29.9% (n=87) vs 17.7% (n=96) placebo @ 52wk80 mg/40 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
30.2% (n=248) vs 18.3% (n=246) placebo @ 52wk160/80/40
NCT00408629 · Phase 3 · Ulcerative Colitis · phase 3
61.3% (n=31) vs 33.3% (n=12) placebo @ 52wkstandard dose
NCT02065557 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
67.7% (n=31) vs 33.3% (n=12) placebo @ 52wkhigh dose
NCT02065557 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
57.6% (n=33) vs 33.3% (n=12) placebo @ 52wkstandard dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
65.7% (n=35) vs 33.3% (n=12) placebo @ 52wkhigh dose
NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3
Sustained Clinical 23.8% (n=248) vs 12.2% (n=246) placebo160/80/40
responder rate · % of participants
NCT00408629 · Phase 3 · Ulcerative Colitis · phase 3
Endoscopic Improvement 44.4% (n=90) vs 30.2% (n=96) placebo @ 8wk160 mg/80 mg
responder rate · % of participants
Induction
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 2 more results
39.1% (n=87) vs 30.2% (n=96) placebo @ 8wk80 mg/40 mg
NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
41.1% (n=248) vs 31.7% (n=246) placebo @ 8wk160/80/40
NCT00408629 · Phase 3 · Ulcerative Colitis · phase 3

+ 51 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: adalimumab's landscape · SOR102's landscape